FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3205631367> ?p ?o ?g. }

• W3205631367 abstract "The Global Initiative for Asthma recommends the use of as-needed low-dose inhaled corticosteroid (ICS)-formoterol as a preferred controller therapy for patients with mild asthma. These recommendations were based, in part, on evidence from the SYGMA 1 and 2 studies of as-needed budesonide-formoterol. This analysis aimed to compare the cost-effectiveness of as-needed budesonide-formoterol to low-dose maintenance ICS plus as-needed short-acting β2-agonist (SABA) in patients with mild asthma.A Markov cohort model was designed that included three possible health states (non-exacerbation, severe exacerbation, and death) to compare as-needed budesonide-formoterol 200-6 μg to twice-daily budesonide 200 μg maintenance therapy (low-dose ICS) plus as-needed terbutaline 0.5 mg (SABA). The deterministic base-case analysis used severe exacerbation, adverse event (AE), and healthcare resource use data from SYGMA 2, and was conducted from a Canadian public payer perspective with a 50-year time horizon, and a discount rate of 1.5% per annum. Moderate exacerbation was modelled on data from SYGMA 1 in sensitivity analyses. Utility values were derived from SYGMA 2 quality of life data. All-cause- and asthma-related mortality rates and costs (reported in 2019 Canadian dollars) were based on published data, using Canada-specific values where available. One-way deterministic sensitivity, probabilistic sensitivity, and eight scenario analyses were conducted to examine the robustness of the results.As-needed budesonide-formoterol was the dominant treatment option in the base-case analysis, providing incremental cost savings of $9882 per patient and quality-adjusted life year (QALY) gains of 0.002 versus low-dose maintenance ICS plus as-needed SABA over a 50-year time horizon. Using a willingness-to-pay threshold of $50,000/QALY ($100,000/QALY), as-needed budesonide-formoterol had a 94% (95%) probability of being cost-effective compared with maintenance ICS plus as-needed SABA. Cost-saving was mostly driven by lower overall medication and AE-related costs. As-needed budesonide-formoterol remained the dominant treatment in sensitivity and scenario analyses.As-needed budesonide-formoterol is a cost-saving option for the treatment of mild asthma from the perspective of the Canadian public payer compared with low-dose maintenance ICS plus as-needed SABA." @default.
• W3205631367 created "2021-10-25" @default.
• W3205631367 creator A5023192416 @default.
• W3205631367 creator A5026242254 @default.
• W3205631367 creator A5035835345 @default.
• W3205631367 creator A5045152912 @default.
• W3205631367 creator A5054105827 @default.
• W3205631367 creator A5059987874 @default.
• W3205631367 creator A5067553502 @default.
• W3205631367 date "2021-10-12" @default.
• W3205631367 modified "2023-10-16" @default.
• W3205631367 title "The cost-effectiveness of as-needed budesonide-formoterol versus low-dose inhaled corticosteroid maintenance therapy in patients with mild asthma in Canada" @default.
• W3205631367 cites W161823661 @default.
• W3205631367 cites W1970708453 @default.
• W3205631367 cites W1994623641 @default.
• W3205631367 cites W1996417170 @default.
• W3205631367 cites W2014545680 @default.
• W3205631367 cites W2021351287 @default.
• W3205631367 cites W2030556594 @default.
• W3205631367 cites W2049632078 @default.
• W3205631367 cites W2062076030 @default.
• W3205631367 cites W2085902327 @default.
• W3205631367 cites W2119771117 @default.
• W3205631367 cites W2137334142 @default.
• W3205631367 cites W2141024340 @default.
• W3205631367 cites W2141896850 @default.
• W3205631367 cites W2144317367 @default.
• W3205631367 cites W2166394031 @default.
• W3205631367 cites W2487414582 @default.
• W3205631367 cites W2601675613 @default.
• W3205631367 cites W2746827280 @default.
• W3205631367 cites W2753097505 @default.
• W3205631367 cites W2789889042 @default.
• W3205631367 cites W2796156341 @default.
• W3205631367 cites W2804556773 @default.
• W3205631367 cites W2804974483 @default.
• W3205631367 cites W2914185992 @default.
• W3205631367 cites W2946771756 @default.
• W3205631367 cites W2954327547 @default.
• W3205631367 cites W2969375889 @default.
• W3205631367 cites W2999425512 @default.
• W3205631367 cites W3038582849 @default.
• W3205631367 cites W3096362429 @default.
• W3205631367 cites W3097387385 @default.
• W3205631367 cites W3128420623 @default.
• W3205631367 cites W3131215500 @default.
• W3205631367 doi "https://doi.org/10.1186/s13223-021-00610-w" @default.
• W3205631367 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8507225" @default.
• W3205631367 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34641954" @default.
• W3205631367 hasPublicationYear "2021" @default.
• W3205631367 type Work @default.
• W3205631367 sameAs 3205631367 @default.
• W3205631367 citedByCount "4" @default.
• W3205631367 countsByYear W32056313672022 @default.
• W3205631367 countsByYear W32056313672023 @default.
• W3205631367 crossrefType "journal-article" @default.
• W3205631367 hasAuthorship W3205631367A5023192416 @default.
• W3205631367 hasAuthorship W3205631367A5026242254 @default.
• W3205631367 hasAuthorship W3205631367A5035835345 @default.
• W3205631367 hasAuthorship W3205631367A5045152912 @default.
• W3205631367 hasAuthorship W3205631367A5054105827 @default.
• W3205631367 hasAuthorship W3205631367A5059987874 @default.
• W3205631367 hasAuthorship W3205631367A5067553502 @default.
• W3205631367 hasBestOaLocation W32056313671 @default.
• W3205631367 hasConcept C126322002 @default.
• W3205631367 hasConcept C194828623 @default.
• W3205631367 hasConcept C197934379 @default.
• W3205631367 hasConcept C2776042228 @default.
• W3205631367 hasConcept C2776136866 @default.
• W3205631367 hasConcept C2776694085 @default.
• W3205631367 hasConcept C2776804153 @default.
• W3205631367 hasConcept C2777014857 @default.
• W3205631367 hasConcept C2777450039 @default.
• W3205631367 hasConcept C2778283404 @default.
• W3205631367 hasConcept C2779871671 @default.
• W3205631367 hasConcept C2780252434 @default.
• W3205631367 hasConcept C2909082789 @default.
• W3205631367 hasConcept C71924100 @default.
• W3205631367 hasConceptScore W3205631367C126322002 @default.
• W3205631367 hasConceptScore W3205631367C194828623 @default.
• W3205631367 hasConceptScore W3205631367C197934379 @default.
• W3205631367 hasConceptScore W3205631367C2776042228 @default.
• W3205631367 hasConceptScore W3205631367C2776136866 @default.
• W3205631367 hasConceptScore W3205631367C2776694085 @default.
• W3205631367 hasConceptScore W3205631367C2776804153 @default.
• W3205631367 hasConceptScore W3205631367C2777014857 @default.
• W3205631367 hasConceptScore W3205631367C2777450039 @default.
• W3205631367 hasConceptScore W3205631367C2778283404 @default.
• W3205631367 hasConceptScore W3205631367C2779871671 @default.
• W3205631367 hasConceptScore W3205631367C2780252434 @default.
• W3205631367 hasConceptScore W3205631367C2909082789 @default.
• W3205631367 hasConceptScore W3205631367C71924100 @default.
• W3205631367 hasFunder F4320307770 @default.
• W3205631367 hasIssue "1" @default.
• W3205631367 hasLocation W32056313671 @default.
• W3205631367 hasLocation W32056313672 @default.
• W3205631367 hasLocation W32056313673 @default.
• W3205631367 hasLocation W32056313674 @default.
• W3205631367 hasOpenAccess W3205631367 @default.
• W3205631367 hasPrimaryLocation W32056313671 @default.

• next